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Abstract: Chronic stable angina is a debilitating illness affecting at least 6.6 million US 
residents. Despite being optimally treated by pharmacotherapy and revascularization up to 
26% of patients still experience angina. Diabetes mellitus is a common co-morbid condition in 
angina patients. Several new investigational medications are being tested for chronic angina. 
Advances in understanding of myocardial ischemia have prompted evaluation of a number 
of new antianginal strategies. In this review we discuss the utility of ranolazine, a recently 
approved novel antianginal agent and its efﬁ  cacy in the diabetic patient population. In addition 
to its antianginal action in diabetic patients with chronic angina, ranolazine may have favorable 
effects on glycated hemoglobin levels.
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Introduction
Chronic stable angina is a debilitating illness affecting atleast 6.6 million US residents 
and approximately 400,000 new cases of stable angina occur each year (Gibbons 
et al 2003). Angina has an annual death rate of 1.6%–3.2% (Gibbons et al 2003). 
Furthermore, up to 26% of patients experience angina despite being treated by 
revascularization and pharmacology (Serruys et al 2001; Holubkov et al 2002).
Chronic stable angina is an insidious manifestation of coronary artery disease 
(CAD). In the US, 5%–15% of the 12 million patients with chronic angina have 
refractory angina. In order to improve the quality of life, the integrated approach to 
CAD should focus on cardiovascular events and prevention of anginal symptoms 
(Bhatt and Stone 2006).
According to National Cholesterol Education Program (NCEP) – Adult Treat-
ment Panel (ATP) III guidelines, diabetes mellitus is a CAD risk equivalent (Adult 
Treatment Panel III 2002). Because diabetic patients have substantial morbidity due 
to CAD, glycated hemoglobin (HbA1c) is an integral part of their CAD management. 
In a meta-analysis on 7,500 diabetic patients a one percentage point increase in HbA1c 
was linked to an 18% increased risk of heart attack or stroke, and a 28% increase in the 
risk of peripheral vascular disease. Accordingly, someone with an HbA1c of 9% has 
a 1.54-times greater risk of a heart attack than someone with an HbA1c level of 6% 
(Selvin et al 2004). According to the American Association of Clinical Endocrinologists 
(AACE) Diabetes Mellitus Clinical Practice Guidelines, a glycemic target of HbA1c 
of ≤6.5% should be encouraged in diabetic patients (AACE 2007).
Stable CAD – multiple treatment options
A multifaceted approach is required in the management of angina. It includes lifestyle 
intervention, medical therapy, and revascularization therapy (percutaneous or surgical). 
Michalsen et al (2006) randomized 101 patients with established CAD to undergo 1-year 
intensive lifestyle modiﬁ  cation vs printed lifestyle advice. Patients assigned to intensive 
lifestyle modiﬁ  cation were extensively informed about the Mediterranean diet; stress Vascular Health and Risk Management 2008:4(4) 820
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management and increased physical activity were strongly 
recommended. Patients in the printed lifestyle advice group 
received written lifestyle informations only. At 1 year, the 
patients who underwent comprehensive lifestyle modiﬁ  cation 
showed signiﬁ  cantly reduced anginal attacks (−54% vs 11%, 
p = 0.01) with concomitant dose reductions in 30% of anti-
ischemic medications (p = 0.004) and improved quality of 
life (Michalsen et al 2006). Boden et al (2007) reported that 
optimal medical therapy and aggressive management of mul-
tiple treatment targets without initial percutaneous coronary 
intervention can be implemented safely in most patients with 
chronic stable angina, even those with objective evidence of 
ischemia and signiﬁ  cant multivessel CAD.
The presence of diabetes in CAD patients doubles the 
risk of adverse cardiovascular events, and aggressive control 
of blood pressure is associated with signiﬁ  cant reduction 
in diabetes risk. Antianginal and antihypertensive regimes 
containing primarily ß-blockers and/or thiazide diuretics alter 
glucose metabolism and/or insulin sensitivity, with a negative 
impact on glucose and HbA1c levels in diabetic and pre-
diabetic patients. Therefore, novel drugs like ranolazine with 
its beneﬁ  cial metabolic effects are crucial for the growing 
number of patients with diabetes mellitus (Cooper-DeHoff 
and Pepine 2006).
New mechanistic approaches 
to myocardial ischemia
Most patients have relative intolerances to maximum doses 
of traditional antianginal agents like ß-blockers, nondihydro-
pyridine (verapamil and diltiazem) calcium channel blockers 
(CCBs), and nitrates. ß-blockers and many CCBs have 
similar depressive hemodynamic and electrophysiological 
effects. Therefore antianginal drugs without these limita-
tions are needed. Advances in understanding of myocardial 
ischemia have prompted evaluation of a number of new 
antianginal strategies (Borer et al 2003; Marzilli and Klein 
2003; Chaitman et al 2005; Chazov et al 2005; Iona Study 
Group 2005; Messin et al 2005; Tardif et al 2005; Vicari et al 
2005; Walker et al 2006).
Ranolazine (Ranexa®, CV Therapeutics) ([(+) N- 
(2, 6-dimethylphenyl)-4(2-hydroxy-3- (2-methoxyphe-
noxy)-propyl)-1-piperazine acetamide dihydrochloride]) 
is a piperazine derivative and was approved in January 27, 
2006 in the US for use in management of chronic angina. It 
is available in oral and intravenous forms but is approved 
only for oral use. Ranolazine is useful in patients who have 
not achieved an adequate response with other antianginal 
medications, and is used in combination with amlodipine, 
ß-blockers, or nitrates. Its therapeutic dose range is 500–1000 
mg twice daily with the maximum recommended dose is 1000 
mg twice daily. Ranolazine undergoes predominantly hepatic 
metabolism with <5% excreted in the urine unchanged 
(Chaitman 2006).
Beneﬁ  cial effects of ranolazine
Ranolazine acts through the following proposed mechanisms.
Effect on cell membrane
Voltage-gated sodium (Na+) channels play a fundamental role 
in the propagation of action potentials in the myocardium. 
During the plateau phase of the action potential, a small 
proportion of Na+ channels either do not close, or close 
and then reopen. This late Na+ channel opening permits 
a sustained Na+ current to enter myocytes during systole. 
During ischemia, this enhanced late intracellular Na+ 
stimulates Na+/Ca2+ exchanger causing increased cytosolic 
calcium (Ca2+). Increased Ca2+ in turn affects electrical and 
contractile dysfunction including high diastolic tension. 
Sustained contraction of ischemic tissue during diastole 
increases myocardial oxygen consumption and compresses 
intramural small vessels, thus reducing nutritive blood 
ﬂ  ow and exacerbating ischemia. Thus Na+-mediated Ca2+ 
overload mediates a vicious cycle of ischemia begetting 
more ischemia. Ranolazine reduces calcium uptake 
indirectly by inhibiting late Na+ channels; thus it preserves 
ionic homeostasis and reduces ischemia-induced contractile 
dysfunction. Ranolazine, in contrast to older antianginal 
medications, works downstream of the ischemic insult, and 
thus may complement the action of traditional antianginal 
medications (Belardinelli et al 2006a, b).
Fraser et al (2006) measured intracellular Na+ and left 
ventricular (LV) function simultaneously in isolated perfused 
rat’s hearts. The sea anemone toxin II (ATX-II) (inhibitor 
of late Na+ channel) was added to the recirculation perfus-
ate. It causes increased diastolic Ca2+ and LV dysfunction. 
Ranolazine when given after ATX-II exposure reverses its 
effect on diastolic Ca2+ with improved LV function.
At the therapeutic concentration, ranolazine inhibits 2 ion 
channels: late Na+ channel and delayed rectiﬁ  er potassium 
channel. Inhibition of delayed rectiﬁ  er potassium channel 
prolongs ventricular action potential, whereas inhibition of 
late Na+ channel has the opposite effects and shortens the 
action potential duration (APD). The net effect of ranolazine 
on APD depends on the relative magnitude of reductions in 
inward Na+ and outward K+ currents during repolarization 
(Scirica et al 2007).Vascular Health and Risk Management 2008:4(4) 821
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As opposed to its effect on ventricular myocardial APD, 
ranolazine does not prolong APD of midmyocardium (M 
cells) and Purkinjee ﬁ  bers at any concentrations. This dis-
tinguishes it from other agents that block delayed rectiﬁ  er 
potassium channel like sotalol, which induces prolongation 
of APD and thus increases the risk of early afterdepolariza-
tions (EADs), which can precipitate torsade de pointes. In an 
experimental study by Antzelevitch et al (2004), ranolazine 
showed a signiﬁ  cant reduction in sotalol-induced prolonga-
tion of APD and EADs. Ranolazine did not induce torsade 
de pointes even at high concentrations. Despite the fact that 
ranolazine lengthens the QT interval, ranolazine-induced 
prolongation of APD is rate dependent (ie, does not display 
reverse rate-dependent prolongation of APD) and is not asso-
ciated with EADs, triggered activity, an increase in spatial 
dispersion of repolarization, or polymorphic ventricular 
tachycardia. Thus ranolazine may have an antiarrhythmic 
property due to its ion channel effects, similar to chronic 
amiodarone therapy.
Ranolazine exerts its antianginal effects without caus-
ing signiﬁ  cant bradycardia and/or lowering systemic blood 
pressure (Pepine and Wolff 1999; Chaitman et al 2004). 
Ranolazine may thus be well suited for patients with lower 
blood pressure or heart rate, in whom the upward titration of 
antianginal medications with important hemodynamic effects 
may not be well tolerated.
Apart from its role in angina, due to its unique mechanism 
of action, ranolazine may be useful in heart failure, certain 
types of cardiac sodium channel mutations, ventricular 
and supraventricular arrhythmias, left ventricular diastolic 
dysfunction with preserved systolic function, and intermittent 
claudication in skeletal muscles. However, further studies are 
needed to support this notion (Chaitman 2006).
Metabolic action
Circulating fatty acid levels rise abruptly during stress of 
acute myocardial ischemia. Compared with carbohydrate 
oxidation, there is an increased oxygen consumption to 
phosphorylate a given amount of adenosine triphosphate 
during fatty acid oxidation, thereby depleting the already low 
levels of oxygen. Further, these elevated fatty acids directly 
suppress the myocardial uptake of oxygen-efﬁ  cient carbohy-
drate substrates like glucose, lactate, and pyruvate, thereby 
promoting oxygen-wasting fatty acid oxidation mechanism 
with the resultant accumulation of lactate, and its deleterious 
effect. Ranolazine appears to shift adenosine triphosphate 
production away from the oxygen-wasting fatty acid oxida-
tion in favor of more oxygen-efﬁ  cient carbohydrate oxidation 
(Chaitman et al 2004a). However, this action appears at very 
high, nontherapeutic blood levels.
Ranolazine clinical trial program 
in chronic stable angina
The Monotherapy Assessment of Ranolazine in Stable 
Angina (MARISA) trial was the ﬁ  rst placebo-controlled trial 
to establish the antianginal and anti-ischemic effects of rano-
lazine. Ranolazine 500, 1000, or 1500 mg given twice daily 
was compared with placebo in a 4-week trial in 191 patients 
with exertional angina. Other antianginals were discontinued 
during the trial except for nitrates. Ranolazine at 500 mg, 
1000 mg, or 1500 mg improved total exercise duration (by 94, 
103, and 116 seconds(s), p < 0.005 compared with placebo) 
and time to angina [27 + 9.5s (p < 0.005), 45.9 + 9.5s, 59.6 
+ 9.6s, p < 0.001]. Of note is that ranolazine had negligible 
effects on heart rate and blood pressure (Chaitman et al 
2004b). Thus it signiﬁ  cantly increased exercise performance 
throughout its dosing interval at all doses studied.
In the Combination Assessment of Ranolazine In Stable 
Angina (CARISA) trial, 823 patients with symptomatic 
chronic angina taking standard doses of atenolol (50 mg), 
amlodipine (5 mg), or diltiazem (180 mg) were randomized 
to receive twice the daily dose of 750 mg or 1000 mg of 
ranolazine or placebo. The choice of background therapy was 
at the discretion of the investigator and the doses were ﬁ  xed 
throughout the study which might contribute to the results. 
Ranolazine reduced the mean number of angina attacks per 
week from 3.3 ± 0.3 for placebo to 2.5 ± 0.2 for 750 mg 
(p = 0.006) to 2.1 ± 0.2 for 1000 mg (p < 0.001) ranolazine. 
It also signiﬁ  cantly reduced nitroglycerine consumption 
(p < 0.02). Exercise duration and time to onset of angina 
increased significantly with ranolazine, independent of 
changes in blood pressure, heart rate, or background therapy, 
and persisted for 12 weeks (Chaitman et al 2004a).
The Efﬁ  cacy of Ranolazine in Chronic Angina (ERICA) 
trial investigated 565 patients with persisting anginal symp-
toms despite maximum recommended doses of amlodipine 
(10 mg) to receive twice daily 1000 mg of ranolazine or pla-
cebo. Ranolazine signiﬁ  cantly reduced frequency of angina 
and nitroglycerine consumption when added to conventional 
antianginal medication (Stone et al 2006).
Thus it is clear that as monotherapy, ranolazine improves 
exercise performance in the absence of clinically meaningful 
pathophysiologic effects, and these studies provide evidence 
of additional antianginal and anti-ischemic efficacy in 
patients who remain symptomatic on standard therapies or 
maximal amlodipine therapy.Vascular Health and Risk Management 2008:4(4) 822
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Challenges in selected populations: 
efﬁ  cacy of ranolazine
Effect of gender
Angina pectoris is more common in women (47%) than in men 
(26%) and with a less favorable prognosis in women. Efﬁ  cacy 
of ranolazine in improving exercise duration is not statistically 
different between men and women (Wenger et al 2007).
Effect of age
As evident from the ERICA trial (Stone et al 2006), the anti-
anginal efﬁ  cacy of ranolazine is independent of age.
Diabetes mellitus
In a post-hoc analysis of the CARISA trial by Timmis et al 
(2006), 189 diabetic patients and 634 nondiabetic patients 
with chronic angina on background atenolol (50 mg), 
diltiazem (180 mg), or amlodipine (5 mg) therapy were 
randomized to placebo, or ranolazine 750 or 1000 mg twice 
daily for 12 weeks, during which exercise tolerance, angina 
frequency, nitroglycerine usage, glucose, HbA1c, and lipids 
were measured. There was no statistically signiﬁ  cant dif-
ference for the effect of ranolazine between diabetic and 
nondiabetic patients in number of weekly anginal episodes 
(p = 0.81) and nitroglycerine use (p = 0.063). There were no 
signiﬁ  cant differences in treatment effects between diabetic 
and nondiabetic patients for exercise duration (p = 0.89), time 
to onset of angina (p = 0.54), or time to ≥1 mm ST-segment 
depression (p = 0.44). There were no signiﬁ  cant differences 
in serum lipid levels and adverse events by treatment effects 
between diabetic and nondiabetic patients.
Though ranolazine did not appear to signiﬁ  cantly lower 
fasting glucose levels in diabetic patients, there was a statisti-
cally signiﬁ  cant reduction of HbA1c with ranolazine compared 
with placebo regardless of concomitant insulin and/or oral 
hypoglycemic therapy [ranolazine 750 and 1000 mg reduced 
HbA1c compared with placebo by 0.48 ± 0.18% (p = 0.008) 
and 0.70 ± 0.18% (p = 0.0002), respectively]. The mean 
baseline HbA1c (%) was 7.46 ± 0.21 in the placebo group, 
7.65 ± 0.20 in the 750 mg ranolazine group, and 7.92 ± 0.21 
in the 1000 mg ranolazine group. Ranolazine 750 and 1000 
mg showed signiﬁ  cant changes in HbA1c levels from baseline 
value (−0.50 ± 0.13 and −0.72 ± 0.13, respectively) compared 
with placebo (−0.02 ± 0.14). The percentage (<7%) of diabetic 
patients with HbA1c was signiﬁ  cantly higher in the ranola-
zine 1000 mg group (p = 0.004). In particular, the decreases 
in HbA1c seen in insulin-treated patients were greater than 
those seen in noninsulin-treated patients. Further, the HbA1c 
concentrations appeared to remain consistent beyond 12 
weeks of ranolazine treatment in the long-term, open-label 
extension study (∼2 years) (Timmis et al 2006).
In the recent Metabolic Efﬁ  ciency With Ranolazine 
for Less Ischemia in Non-ST-Elevation Acute Coronary 
Syndromes – Thrombolysis in Myocardial Infarction 
(MERLIN-TIMI 36) trial (Morrow et al 2007a), 6,560 
patients with nonST-elevation acute coronary syndrome 
at moderate to high risk of recurrent cardiovascular events 
were randomized to receive ranolazine vs placebo within 48 
hours of onset of ischemic symptoms in addition to standard 
therapy for acute coronary syndrome. In the prospective 
validation of the MERLIN-TIMI 36 trial, ranolazine showed 
a signiﬁ  cant reduction in HbA1c at 4 months compared with 
placebo (change from baseline −0.30 vs −0.04, p = 0.001). 
Diabetic patients treated with ranolazine showed a signiﬁ  cant 
decline in HbA1c from 7.5% to 6.8% (change from base-
line −0.64, p < 0.001). Further, diabetic patients were more 
likely to achieve an HbA1c <7% at 4 months when treated 
with ranolazine vs placebo (59% vs 49%, p < 0.001). Also, 
ranolazine-treated diabetic patients showed less worsening 
of hyperglycemia by 1 year of follow-up (14.2% vs 20.6%, 
p < 0.001). Interestingly, in diabetes-free patients at baseline 
(baseline HbA1c of <6%), ranolazine showed reduced inci-
dence of new increase in HbA1c ≥ 6% (95% CI 0.53, 0.88, 
p = 0.003) (Morrow et al 2007b).
Possible explanation for beneﬁ  cial effects 
in diabetes
The above-mentioned beneﬁ  cial effects in diabetics could 
possibly be due to a ranolazine-induced decrease in anginal 
symptoms and increased physical activity, with a resultant 
increase in insulin sensitivity. Ranolazine’s effect on HbA1c 
levels may be speculated by its action on cell membrane or its 
metabolic action. However, future studies should be carried 
out to validate this ﬁ  nding. Other mechanisms through the 
effects of ranolazine on insulin release or decrease in insulin 
resistance need to be explored.
Long-term safety and tolerability 
of ranolazine
Ranolazine is well tolerated in high-risk CAD patients in 
the long term. In The Ranolazine Open Label Experience 
(ROLE) program (Koren et al 2007), 2.8-year mean follow-
up was done for 746 chronic angina patients on ranolazine. 
The most common adverse effects reported were dizziness 
(11.8%) and constipation (10.9%). These complaints led to 
discontinuation in 0.9% and 0.5% of patients, respectively. Vascular Health and Risk Management 2008:4(4) 823
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On ECG, the mean QTc prolongation was 2.4 ms (p < 0.001) 
while QTc prolongation >500 ms was noted in only 1.2% of 
patients. No subjects were withdrawn for QTc prolongation 
and no torsades de pointes was reported. Further, the pres-
ence of diabetes status was not correlated with increased 
adverse event-related discontinuation of ranolazine (relative 
risk 1.04, p = 0.87).
Syncope and postural hypotension can occur with rano-
lazine, likely due to alpha-adrenergic receptor blockage at 
very high doses of up to 2000 mg. It is avoidable by the usual 
practice of initiating ranolazine with the lowest available 
dose and carefully titrating upward based on both efﬁ  cacy 
and tolerability (Chaitman et al 2004a).
In the MERLIN-TIMI 36 trial ranolazine was not effec-
tive in reducing the rate of the composite of cardiovascular 
death and myocardial infarction. But there was a 13.9% 
(p = 0.03) relative reduction in the risk of recurrent ischemia, 
and a lower increase in other antianginal therapy in patients 
in the ranolazine group, with no effect on the composite of 
cardiovascular death or myocardial infarction. Ranolazine did 
not adversely affect the risk of all-cause death, sudden cardiac 
death, or symptomatic documented arrhythmia. Thus, the 
MERLIN-TIMI 36 trial does not support the use of ranolazine 
in acute coronary syndrome, but adds to previous safety data 
and provides additional support for ranolazine as antianginal 
therapy in chronic angina (Morrow et al 2007a).
Of note is that ranolazine-treated patients in the MERLIN-
TIMI 36 trial showed a signiﬁ  cant reduced frequency of tachy- 
and bradyarrhythmias detected by Holter recordings during 
the ﬁ  rst 7 days of randomization (Scirica et al 2007).
On ECG, T-wave notching has been observed at very 
high plasma ranolazine concentrations. Ranolazine is contra-
indicated in patients with pre-existing QT prolongation, on 
QT-prolonging medications, or with hepatic impairment. An 
ECG should be obtained at baseline and follow-up to evalu-
ate effects on QT interval. Small increases in creatinine have 
been observed (>0.1 mg/dL) with ranolazine, which appear 
to be due to inhibition of tubular secretion without any det-
rimental effect on glomerular function. Patients with severe 
renal insufﬁ  ciency should be closely monitored especially 
if the patient is uptitrated to the maximum dose (Chaitman 
2006). This may be of concern especially in diabetics who 
often have concomitant severe renal insufﬁ  ciency.
Ranolazine is an alternative in many patients with chronic 
angina who cannot undergo successful percutaneous or 
surgical revascularization due to anatomic conditions such 
as severe distal vessel disease, small-branch vessel disease, 
or other factors (Berger 2004). Its efﬁ  cacy in diabetics with 
diffuse, multivessel, and small vessel disease may be an 
attractive option, particularly in patients with a favorable 
metabolic proﬁ  le. Prospective randomized studies are neces-
sary in diabetics with ischemia/coronary artery disease, to 
validate the favorable beneﬁ  ts noted in subgroup analysis.
Conclusion
Chronic angina is a chronic debilitating illness. Ranolazine 
is a novel antianginal medication recently approved by the 
FDA for management of refractory angina. It appears to 
be a safe and effective antianginal in the management of 
refractory chronic angina with an advantage of decreased 
angina frequency, increased exercise tolerance, and no 
deleterious effects on hemodynamics. In addition to its anti-
anginal property, ranolazine might have a favorable effect 
on HbA1c levels in diabetic patients.
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